Global Acute Myeloid Leukemia Market, By Disease Type (Myeloblastic, Promyelocytic, and Myelomonocytic), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) - Industry Trends and Forecast to 2030.
Acute Myeloid Leukemia Market Analysis and Size
Acute Myeloid Leukemia (AML) is a cancer affecting the bone marrow and blood. It is characterized by the rapid growth of abnormal myeloid cells, immature white blood cells that normally develop into various mature blood cells. The treatment of AML typically involves a combination of chemotherapy, targeted therapy, and, in some cases, stem cell transplantation. The specific treatment approach depends on factors such as the patient's age, overall health, and specific genetic characteristics of the leukemia cells.
Data Bridge Market Research analyses that the acute myeloid leukemia market, which was USD 2,500.00 million in 2022, would rocket up to USD 5,866.25 million by 2030 and is expected to undergo a CAGR of 11.3% during the forecast period. This indicates that the market value of myeloblastic dominates the product type segment of the acute myeloid leukemia market owing to the increasing aging population.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Acute Myeloid Leukemia Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Global Acute Myeloid Leukemia Market, By Disease Type (Myeloblastic, Promyelocytic, and Myelomonocytic), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico in North America, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, rest of Middle East, Brazil, Argentina and rest of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN (U.S.), Abbott (U.S.), Siemens Healthcare GmbH (Germany), Merck KGAA (Germany), Hologic, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), DiaSorin S.p.A. (U.S.), Illumina, Inc. (U.S.), BIOMÉRIEUX (France), Myriad Genetics, Inc. (U.S.), Quest Diagnostics Incorporated. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), BD (U.S.), Exact Sciences Corporation (U.S.), Time Medical Holding (U.S.), PlexBio (Taiwan), MinFound Medical Systems Co., Ltd (China), Medonica Co. LTD (South Korea), CANON MEDICAL SYSTEMS CORPORATION (Japan), FONAR CORP. (U.S.), Sysmex Corporation (Japan), Epigenomics AG (Germany), Sonic Healthcare (Australia), and SternMed GmbH (Germany) among others
|
|
Market Opportunities
|
|
Market Definition
Acute myeloid leukemia is a hematological cancer originating from blood-forming cells of the bone marrow. In this type of leukemia, the abnormal white blood cells are formed rapidly and gathered in the bone marrow, and thus, eventually affecting the healthy blood cells. Symptoms include easy bruising, fatigue, breathlessness, and bleeding. Increased risk factors such as carcinogens, bold disorders, and genetics expand the market.
Acute Myeloid Leukemia Market Dynamics
Drivers
- Increasing incidence of AML
AML is one of the most common types of leukemia, and its incidence is rising globally, including in the Asia-Pacific region. The growing population and aging demographics contribute to the increasing number of AML cases, which can drive market growth.
- Improving healthcare infrastructure
Many countries in the Asia-Pacific region are investing in their healthcare infrastructure, including cancer treatment facilities and diagnostic capabilities. Expanding and improving healthcare infrastructure can lead to earlier detection and better management of AML, driving market growth.
- Rising awareness and education
Efforts to raise awareness about AML, its symptoms, and available treatment options can contribute to early diagnosis and prompt intervention. Increased education among healthcare professionals and the general population can drive market growth by encouraging timely treatment initiation.
- Advancements in treatment options
Research and development efforts are continually improving the understanding of AML and leading to the development of new treatment options. The availability of innovative therapies, such as targeted therapies and immunotherapies, can positively impact the AML market by providing more effective and personalized treatment options.
Opportunities
- Government initiatives and funding
Government support, funding, and regulatory initiatives aimed at improving cancer care can significantly impact the AML market. Policies promoting early detection, access to treatment, and affordable healthcare can drive market growth.
- Collaboration and partnerships
Collaboration among pharmaceutical companies, research institutions, and healthcare providers can foster innovation and accelerate the development of new therapies. Collaborative efforts to conduct clinical trials, share data, and exchange knowledge can contribute to advancements in AML treatment and drive market growth.
Restraints/Challenges
- Lack of awareness and education
Despite efforts to raise awareness about AML, there may still be gaps in knowledge and understanding among healthcare professionals, patients, and the general population. Limited awareness can result in delayed diagnosis, inadequate treatment decisions, and suboptimal patient outcomes.
- Resistance to conventional therapies
AML is known for its heterogeneity and the development of drug resistance over time. Some patients may not respond adequately to conventional chemotherapy regimens, leading to limited treatment options and poorer prognoses.
This acute myeloid leukemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute myeloid leukemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System. This next-generation digital PCR system helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases
- In May 2022, Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to the company’s growing oncology portfolio. This results in increasing liquid biopsy space for precise tumor tests.
Global Acute Myeloid Leukemia Market Scope
The acute myeloid leukemia market is segmented on the basis of disease type, treatment type, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Myeloblastic
- Promyelocytic
- Myelomonocytic
Treatment Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormone Therapy
- Others
Route of Administration
- Oral
- Parentral
- Others
End User
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Acute Myeloid Leukemia Market Regional Analysis/Insights
The acute myeloid leukemia market is analysed and market size insights and trends are provided by country, disease type, treatment type, route of administration, end users, and distribution channel as referenced above.
The countries covered in the acute myeloid leukemia market report are U.S., Canada, Mexico in North America, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, rest of Middle East, Brazil, Argentina and rest of South America
North America is expected to dominate the market because of the increasing prevalence of acute myeloid leukemia, growing investment in healthcare infrastructure is also boosting the growth of the market.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The acute myeloid leukemia market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for acute myeloid leukemia market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the acute myeloid leukemia market. The data is available for historic period 2010-2020.
Competitive Landscape and Acute Myeloid Leukemia Market Share Analysis
The acute myeloid leukemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acute myeloid leukemia market.
Some of the major players operating in the acute myeloid leukemia market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Thermo Fisher Scientific, Inc. (U.S.)
- QIAGEN (U.S.)
- Abbott (U.S.)
- Siemens Healthcare GmbH (Germany)
- Merck KGAA (Germany)
- Hologic, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- DiaSorin S.p.A. (U.S.)
- Illumina, Inc. (U.S.)
- BIOMÉRIEUX (France)
- Myriad Genetics, Inc. (U.S.)
- Quest Diagnostics Incorporated. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- BD (U.S.)
- Exact Sciences Corporation (U.S.)
- Time Medical Holding (U.S.)
- PlexBio (Taiwan)
- MinFound Medical Systems Co., Ltd (China)
- Medonica Co. LTD (South Korea)
- CANON MEDICAL SYSTEMS CORPORATION (Japan)
- FONAR CORP. (U.S.)
- Sysmex Corporation (Japan)
- Epigenomics AG (Germany)
- Sonic Healthcare (Australia)
- SternMed GmbH (Germany)
SKU-